Clear Search

Showing 7 results for “Kollmeier AP”.

September 2023

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589

Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.

Mais…

April 2023

Eficácia e segurança multidomínio de guselkumabe durante um ano em pacientes com artrite psoriática ativa com e sem exposição prévia a inibidores do fator de necrose tumoral: análise do estudo de fase 3, randomizado, controlado com placebo DISCOVER-1

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523

TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.

Mais…

March 2023

Baixas Taxas de Progressão Radiográfica Associadas com Eficácia Clínica em até 2 anos de Seguimento Após Tratamento com Guselkumab: Resultados de um Ensaio Clínico Randomizado de Fase 3, Duplo-Cego, Controlado com Placebo com Pacientes Naïve a Biológicos com Artrite Psoriásica Ativa

RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789

Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.

Mais…

February 2023

O Efeito de Guselkumabe na Inibição Radiográfica em Pacientes com Artrite Psoriásica Ativa: protocolo do estudo APEX, um ensaio de fase 3b, multicêntrico, randomizado, duplo-cego, controlado com placebo

Trials. 2023 doi: 10.1186/s13063-022-06945-y

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Mais…

Segurança de Guselkumabe com ou sem Terapia Prévia com Inibidor de TNF-a: Resultados agrupados de quatro estudos em pacientes com artrite psoriásica

J Rheumatol. 2023 jrheum

These results demonstrate that guselkumab was well tolerated in studies continuing for 1 to 2 years among patients with moderate-to-severe PsA regardless of TNFi experience and concomitant MTX use. The objective of this study was to assess pooled safety results from Phase 2/3 studies of guselkumab in TNFi-naïve and experienced PsA patients.

Mais…

September 2022

The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0

In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.

Mais…

July 2022

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375

This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.

Mais…